US FDA Has Done Over 200 ‘Mission Critical’ Inspections During COVID
Executive Summary
For now, agency appears to be in early stages of testing alternative inspection models beyond the flexibility it has been applying throughout the pandemic.
You may also be interested in...
US FDA Inspections By The Numbers: Very Few During COVID
GAO report offers new data on the impact of COVID on FDA’s drug inspections. (It was big.)
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.